AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$ALEC

Berkley Neil Lindsay sold $78K of ALEC

Berkley Neil Lindsay (CFO & Chief Business Officer) sold 29,251 shares of Alector, Inc. (ALEC) at $2.66 on 2026-09-03.

Original reporting
SEC EDGAR · Berkley Neil Lindsay
Published Sep 4, 2026, 9:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 9:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ALEC
Neutral
high confidence
Mentioned
$ALEC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALECNeutralLow
01

Why it matters

The CFO's sale is modest and does not alter control or strategic direction.

02

Market read

Insider sale is routine; limited trading relevance.

03

What to watch

Potential upcoming corporate actions not disclosed in this filing.

Relevance 3/10Novelty 4/10Timing: post-market 2026-09-03

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$ALECNeutralHigh confidence
Context

CFO Berkley Neil Lindsay sold 29,251 shares for $77,948, reducing his stake to 350,649 shares.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale amount is small relative to market cap and typical insider trading volumes.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could signal insider concern, but size is too small to be meaningful.

Key entities

  • Company
    Alector, Inc.

    Biotech firm developing neurodegenerative disease therapies.

  • Individual
    Berkley Neil Lindsay

    Chief Financial Officer and Chief Business Officer of Alector.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ALEC insider trading history →

Related articles

OCT 7
MedAI 8/10

Genentech pays Alector $100m for Parkinson drug

Genentech paid Alector $100m upfront for global rights to AL050, a Parkinson's drug. Alector may receive up to $1.17b in milestones. AL050 targets GCase deficiency, a factor in Parkinson's. The deal extends Alector's cash runway to 2029, supporting other Alzheimer's and Parkinson's programs.

bioxconomy.com2 min
OCT 6
HighAI 9/10

Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion

Roche will pay up to $1.27 billion to license Alector's experimental Parkinson's therapy, AL050. The deal includes a $100 million upfront payment and potential milestone payments. Alector's shares surged 72% in premarket trading. Roche's Genentech unit will handle development and commercialization, with Alector eligible for royalties.

ksl.com2 min
OCT 5
$ALECHigh

Alector (ALEC) Shares Jump 22% on Genentech Licensing Deal for A

Alector Inc (ALEC) shares rose 22% after announcing a licensing deal with Genentech for its AL050 program. The deal includes a $100M upfront payment and potential milestone payments up to $1.17B. Alector's P/S ratio is 17.46, higher than historical and industry averages, reflecting growth expectations. The company's GF Score is 31/100, indicating weak fundamentals but some momentum.

gurufocus.com2 min